Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618160 | 1.00 | AAK1 (0.33) | AAK1RAB9AKMT2AUSP30GPR119 | |
| SCHEMBL3325118 | 0.81 | CHRNB2 (0.49) | RAB9AKMT2A | |
| SCHEMBL3325125 | 0.81 | CHRNB2 (0.49) | RAB9AKMT2A | |
| SCHEMBL7170705 | 0.80 | AAK1 (0.33) | AAK1RAB9A | |
| SCHEMBL7170697 | 0.80 | AAK1 (0.33) | AAK1RAB9A | |
| SCHEMBL7170974 | 0.80 | AAK1 (0.33) | AAK1RAB9A | |
| SCHEMBL7170985 | 0.80 | AAK1 (0.33) | AAK1RAB9A | |
| SCHEMBL7170702 | 0.80 | AAK1 (0.33) | AAK1RAB9A | |
| SCHEMBL7099305 | 0.79 | AAK1 (0.37) | AAK1USP30ALDH1A1 | |
| SCHEMBL619926 | 0.78 | AAK1 (0.33) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9107915-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8778978-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580826-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2371818-B1 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102643228-A | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC | 2012-08-22 | — | — | CN | disclosed |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MUNOZ JULIO A (US) | 2012-02-16 | — | — | US | disclosed |
| US-8053451-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1317267-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | Targacept, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1311265-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | Targacept, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | AAK1 4035/4885RAB9A 319/4885KMT2A 603/4885 |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | AAK1 4066/4885RAB9A 321/4885KMT2A 597/4885 |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | AAK1 4066/4885RAB9A 321/4885KMT2A 597/4885 |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | AAK1 4411/4885RAB9A 3246/4885KMT2A 1286/4885 |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | AAK1 4035/4885RAB9A 319/4885KMT2A 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.